磺达肝癸钠和依诺肝素对不稳定型心绞痛的疗效及安全性比较

Comparison of efficacy and safety of fondaparinux and enoxaparin in the treatment of unstable angina pectoris

目的比较磺达肝癸钠和依诺肝素在不稳定型心绞痛（UAP）治疗中的有效性及安全性。方法选择UAP患者128例,随机分为2组：A组68例,B组60例,2组均给予常规抗UAP治疗。A组加用磺达肝癸钠2.5 mg皮下注射,每天1次,持续3~8 d（平均5.5 d）;B组加用依诺肝素1 mg/kg,每天2次皮下注射,持续5~7 d（平均5.8 d）。疗程均为2周。比较2组疗效及安全性。结果 2组患者在严重心血管事件如死亡、心肌梗死、恶性心律失常及心绞痛发作发生率均无明显差异（P均〉0.05）,而严重出血（脑出血、腹膜腔出血、呕血、便血＋＋＋＋）及轻度出血（皮下瘀斑、牙龈出血、血尿、便血＋＋＋以下）发生率比较,A组较B组有明显下降（P均〈0.05）。结论磺达肝癸钠和依诺肝素治疗UAP患者疗效相似,但磺达肝癸钠出血发生率较依诺肝素明显降低。

Objective To evaluate the efficacy and safety of fondaparinux and enoxaparin in the treatment of unstable angina pectoris（UAP）.Methods A total of 128 patients with UAP were randomly divided into fondaparinux group（group A,68 cases） and enoxaparin group（group B,60 cases）.On top of conventional anti-UAP treatment,fondaparinux was added（2.5 mg daily subcutaneous injection for 3-8 days） in group A,and enoxaparin（1 mg/kg twice a day for 5-7 days） was added in group B.The efficacy and safety were compared between group A and group B.Results There was no significant difference in incidence of cardiac events（death,myocardial infraction,malignant arrhythmia and onset of UAP）,but the incidence of bleeding（including severe and minor bleeding） was lower in group A than that in group B.Conclusions Fondaparinux and enoxaparin have the same efficacy,but fondaparinux has lower incidence of bleeding in the treatment of UAP,thereby has a better safety.